Similar articles

• Pharmacological control of platelet function.

  Clutton P, Folts JD, Freedman JE. Clutton P, et al. Pharmacol Res. 2001 Oct;44(4):255-64. doi: 10.1006/phrs.2001.0861. Pharmacol Res. 2001. PMID: 11592859 Review.
• Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.

  Penz SM, Reininger AJ, Toth O, Deckmyn H, Brandl R, Siess W. Penz SM, et al. Thromb Haemost. 2007 Mar;97(3):435-43. Thromb Haemost. 2007. PMID: 17334511
• [Pharmazie in unserer Zeit 4/2009].

  Alban S, Dingermann T. Alban S, et al. Pharm Unserer Zeit. 2009;38(4):295. doi: 10.1002/pauz.200990042. Pharm Unserer Zeit. 2009. PMID: 19572344 German. No abstract available.
• [Various therapy options. Medical Chemistry of platelet aggregation inhibitors].

  Zettl H, Schubert-Zsilavecz M. Zettl H, et al. Pharm Unserer Zeit. 2009;38(4):314-9. doi: 10.1002/pauz.200900320. Pharm Unserer Zeit. 2009. PMID: 19572349 Review. German. No abstract available.
• Effects of anticoagulants used during blood collection on human platelet function.

  May JA, Heptinstall S. May JA, et al. Methods Mol Biol. 2004;272:3-11. doi: 10.1385/1-59259-782-3:003. Methods Mol Biol. 2004. PMID: 15226530 No abstract available.